CDKs are attractive targets for cancer therapy due to their central role in cell cycle regulation. Several CDK inhibitors have been developed and are in clinical use. These inhibitors are designed to specifically bind to the ATP-binding site of CDKs, blocking their kinase activity. Selective inhibitors like Abemaciclib and Ribociclib target CDK4/6 and have shown efficacy in treating various cancers.
